Intelligent Bio Solutions Advances Non-Invasive Drug Testing Technology with FDA Clearance
TL;DR
INBS poised for 2025 U.S. launch with non-invasive drug screening system, offering potential first-mover advantage in diverse industries.
INBS preparing for U.S. launch with FDA 510(k) submission, showing 94.1% accuracy in detecting opiates via fingerprint sweat.
INBS' non-invasive drug screening system contributes to a safer environment by enabling rapid and accurate detection of recent drug use.
INBS's Intelligent Fingerprinting Drug Screening System gaining global traction for its innovative approach to combating drug use.
Found this article helpful?
Share it with your network and spread the knowledge!
Intelligent Bio Solutions is advancing its non-invasive drug screening technology through the FDA clearance process, with plans for a 2025 U.S. market launch. The company's Intelligent Fingerprinting Drug Screening System offers a rapid, portable method for detecting recent drug use through fingerprint sweat analysis.
The company submitted a 510(k) premarket notification to the FDA, seeking clearance for its opiate test system. Validation studies demonstrated 94.1% accuracy in detecting opiates, highlighting the technology's potential precision in workplace drug screening.
Currently operating in 24 countries with over 450 commercial accounts, Intelligent Bio Solutions has already gained significant traction across diverse industries including logistics, mining, retail, and marine operations. The company is expanding its distributor network to support localized growth ahead of its U.S. market entry.
The drug screening system represents a significant advancement in workplace safety technologies, offering a non-invasive, quick, and portable alternative to traditional drug testing methods. Its potential applications span multiple sectors where employee drug screening is critical for maintaining safety and productivity.
With growing global demand for efficient and less intrusive drug testing solutions, Intelligent Bio Solutions' technology could revolutionize how organizations approach workplace substance use screening.
Curated from InvestorBrandNetwork (IBN)
